CTOs on the Move


 
EXOS is a leader in the field of human performance, a category it created more than 15 years ago. Today, EXOS employs more than 3,500 people in over 400 locations worldwide. With award-winning facilities, technology, and services, EXOS helps people take control of their health and performance so they can achieve what matters most to them. EXOS is trusted by hundreds of clients, including one-quarter of Fortune 100 companies, world champions in sports, and leaders in health care, military, and community organizations.
  • Number of Employees: 1K-5K
  • Annual Revenue: $100-250 Million
  • www.teamexos.com
  • 2629 East Rose Garden Lane
    Phoenix, AZ USA 85050
  • Phone: 480.449.9000

Executives

Name Title Contact Details
Yvette Pasqua
Chief Technology Officer Profile
Thomas Glaser
Chief Information Security Officer Profile

Similar Companies

Ashley Glen Assisted Living

Ashley Glen Assisted Living is a Peachtree City, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Spinal Kinetics

Spinal Kinetics is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Sunnyvale, CA. To find more information about Spinal Kinetics, please visit www.spinalkinetics.com

EarQ

Schedule your appointment with a local hearing healthcare professional. See available times and providers, book online with EarQ, and start hearing better!

Innogenetics NV

Innogenetics NV is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Innogenetics NV is based in Alpharetta, GA. You can find more information on Innogenetics NV at www.innogenetics.com

HedgePath Pharmaceuticals

HedgePath Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize innovative therapeutics for patients with cancer. The Company may also explore acquiring or licensing innovative therapeutics addressing unmet needs and orphan indications beyond cancer. We are focused on the development of therapies for more than one type of cancer, with initial emphasis in the U.S. market, based upon repurposing the currently marketed antifungal drug itraconazole for new indications in oncology.